Skip to main content
Figure 6 | BMC Medical Genomics

Figure 6

From: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Figure 6

Waterfall plot of RAS signature score in patients who experienced disease control (blue) or progressive disease (red) after Cetuximab therapy. The Y-axis shows RAS signature score relative to the mean of all tumors in this dataset. Fisher's exact test p-value for the difference between the disease control and progressive disease groups is shown. Data is derived from [5], and includes all patients with known response.

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us